AARD Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 16.24%, SMA50 24.13%, SMA200 30.62%). The stock’s 14-day RSI is 62.43 (firm momentum), while the ATR of 1.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.69% below its high and over 198.16% above its low. Average 10-day trading volume of 344.33 thousand shares is significantly above the 3-month average of 191.85 thousand, indicating heightened recent market interest.

Aardvark Therapeutics, Inc. Common Stock has 21.77 million shares outstanding. The public float is 11.10 million shares, elevated short interest at 9.18% of float. This equals 1.30 million shares. The short ratio is 8.44 days. Institutional investors hold 59.05% of the float. Insiders own 14.3%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Wall Street analysts project EPS growth of 7.39% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $18.00. The high target offers 243.64% upside. The low target suggests 23.71% downside. The mean target is $29.94. This offers 105.77% upside. Aardvark Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -8.36%. The prior quarter beat by 26.92%. Over the last six quarters, Apple has recorded several small beats. These include 26.92% in August 13, 2025.

Aardvark Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.71. This means the shares are trading above this model’s fair value.

Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) closed at $14.28 USD, losing -$0.27 (-1.83%) from the previous close of $14.55. The stock is currently mid-range between its 52-week high and low $4.88 and $19.58. With a market capitalization of about $310.99 million, Aardvark Therapeutics, Inc. Common Stock is classified as a small-cap and shows higher-than-market volatility (beta ~3.62). Key stats such as the average daily volume over the past year has been around 197.07 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Aardvark Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tien-Li Lee, the company employs approximately 22 people and listed since February 13, 2025. Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.

Aardvark Therapeutics, Inc. Common Stock trades at a P/E ratio of -6.49, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.59 suggesting the stock is closer to book value. The P/FCF stands at -7.02, also below market averages.

currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Aardvark Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -6.49. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $29.94, suggesting 105.77% upside. Our AI forecast model points to short-term strength (7.7% over two weeks), a medium-term rise (69.35% over three months), and a longer-term gain (113.54% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Aardvark Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.7%, with price expected at $15.67 by January 05, 2026, within a range of $13.95 to $17.20 3-Month Outlook: Projected rise of 69.35%, reaching $24.64 by March 20, 2026, with a range of $24.29 to $24.96. 1-Year Outlook: Projected gain of 113.54%, with price at $31.07 by December 22, 2026, within a range of $30.80 to $31.35.